Literature DB >> 6217214

Diagnosis of cutaneous T cell lymphoma by use of monoclonal antibodies reactive with tumor-associated antigens.

C L Berger, S Morrison, A Chu, J Patterson, A Estabrook, S Takezaki, J Sharon, D Warburton, O Irigoyen, R L Edelson.   

Abstract

Two murine monoclonal antibodies (BE1 and BE2), produced by using leukemic helper T cells from a patient with cutaneous T-cell lymphoma (CTCL) as immunogens, reacted selectively with CTCL lymphocytes and some transformed cultured lymphocytes, as determined by radioimmunoassay (RIA) and indirect immunofluorescence (IIF). BE1 reacted significantly (P less than or equal to 0.001) with leukemic CTCL lymphocytes and with CTCL cells from infiltrated lymph nodes (RIA, mean +/- SD = 776 +/- 275 cpm), as compared with background counts (263 +/- 68). BE1 binding to normal blood mononuclear cells (RIA, mean +/- SD = 283 +/- 58 cpm) was indistinguishable from background. BE1 also reacted with Epstein-Barr virus (EBV)-transformed B-cell lines (RIA, mean +/- SD = 794 +/- 230) and some long-term T-cell lines. BE1 did not react with the majority of lymphoid cell lines or tumor cell lines tested. BE1 also did not react with any normal tissues screened by IIF. BE1 precipitated a molecule from CTCL cells that, under reducing conditions, has two components with molecular mass of 27,200 and 25,800 D. BE2 also reacted significantly (P less than or equal to 0.001) with CTCL cells from two of four patients (RIA, mean +/- SD = 519 +/- 113 cpm). The binding of BE2 to normal mononuclear cells was indistinguishable from background (309 +/- 38 cpm). BE2 also reacted with an antigen present on EBV-B-cell lines (RIA, mean +/- SD = 654 +/- 194) and MOLT 3 and HUT 78 T-cell lines. BE2 reacted with an antigen expressed on a subpopulation of lymphocytes from five of eight patients with B-cell CLL studied by IIF (mean +/- SD = 18 +/- 6). Other long-term T-cell lines and tumor cell lines studied by IIF were unreactive with BE2. BE2 did not react with any of the normal tissues studied. BE2 precipitated a molecule (78,000 D) from CTCL cells and EBV-B cells with a single component under reducing conditions. Immunoperoxidase-labeled BE1 and BE2 reacted with CTCL cells in frozen sections of infiltrated lymph nodes and skin. In addition, BE1 and BE2 reacted with blood lymphocytes from 16 of 21 patients whose CTCL had otherwise been considered localized to skin. These two monoclonal antibodies react with tumor antigens associated with CTCL and appear to be useful in the diagnosis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6217214      PMCID: PMC370337          DOI: 10.1172/jci110719

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Candidate leukaemia-specific antigen in man.

Authors:  G Brown; N Hogg; M Greaves
Journal:  Nature       Date:  1975-12-04       Impact factor: 49.962

3.  Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes.

Authors:  M S Weiner; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1973-12       Impact factor: 22.113

4.  Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Human leukemia cell antigens: serologic characterization with xenoantisera.

Authors:  T Mohanakumar; R S Metzgar; D S Miller
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

6.  Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings.

Authors:  E H Epstein; D L Levin; J D Croft; M A Lutzner
Journal:  Medicine (Baltimore)       Date:  1972-01       Impact factor: 1.889

7.  Enzymic iodination. A probe for accessible surface proteins of normal and neoplastic lymphocytes.

Authors:  J J Marchalonis; R E Cone; V Santer
Journal:  Biochem J       Date:  1971-10       Impact factor: 3.857

8.  Cerebriform (Sézary like) mononuclear cells in healthy individuals: a morphologically distinct population of T cells. Relationship with mycosis fungoides and Sézary's syndrome.

Authors:  C J Meyer; A W van Leeuwen; E M van der Loo; L B van de Putte; W A van Vloten
Journal:  Virchows Arch B Cell Pathol       Date:  1977-10-27

9.  The Sézary syndrome lymphoid cell: abnormal surface properties and mitogen responsiveness.

Authors:  R Braylan; D Variakojis; S Yachnin
Journal:  Br J Haematol       Date:  1975-12       Impact factor: 6.998

10.  The Sézary syndrome: a malignant proliferation of helper T cells.

Authors:  S Broder; R L Edelson; M A Lutzner; D L Nelson; R P MacDermott; M E Durm; C K Goldman; B D Meade; T A Waldmann
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

View more
  5 in total

1.  Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides.

Authors:  K Kaltoft; S Bisballe; T Dyrberg; E Boel; P B Rasmussen; K Thestrup-Pedersen
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

2.  Reactivity of monoclonal antibody BE 2 in different stages of mycosis fungoides and in benign dermal infiltrates.

Authors:  P Kaudewitz; R Soldner; G Burg; T Bieber; C Berger; R Edelson; P Rieber; O Braun-Falco
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

3.  Photopheresis--extracorporeal irradiation of 8-MOP containing blood--a new therapeutic modality.

Authors:  R M Knobler
Journal:  Blut       Date:  1987-04

4.  Lymphomatoid papulosis with possible progression to lymphoma: T-cell subpopulations as prognostic indicators.

Authors:  M Shaw; A C Chu; D A Fenton; M M Black
Journal:  J R Soc Med       Date:  1984       Impact factor: 5.344

5.  Actinic reticuloid simulating Sézary syndrome. Report of two cases.

Authors:  J Toonstra; H van Weelden; F H Gmelig Meyling; S C van der Putte; S I Schiere; H Baart de la Faille
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.